{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ARTV",
  "name": "Artiva Biotherapeutics, Inc.",
  "url": "https://frontierpicks.com/dossiers/ARTV/",
  "json_url": "https://frontierpicks.com/dossiers/ARTV.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Artiva Biotherapeutics’ AlloNK thesis hinges on expanded rheumatoid arthritis data and pivotal-trial initiation by year-end 2026. Those milestones must arrive before a weekly close below $8.61 invalidates the market case.",
  "invalidation_trigger": "A weekly close below $8.61, the September 18, 2026 reference close, invalidates the market-stabilization thesis; missing the promised expanded rheumatoid arthritis data or trial initiation by year-end separately breaks the development timetable.",
  "catalyst_date": "2026-09-24",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [],
  "body_markdown": "## Current Thesis\n\nArtiva Biotherapeutics’ thesis is that AlloNK can advance from early autoimmune-disease results into pivotal development; expanded rheumatoid arthritis data and trial initiation by year-end would confirm that transition. This is a development-milestone thesis, not an established efficacy conclusion. Artiva’s September 8, 2026 update retained those milestones for the second half of 2026. [September 8 company update](https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Provides-Update-on-Planned-AlloNK-Data-Disclosures-and-Development-Milestones-for-the-Remainder-of-2026/default.aspx)\n\nAs an inference, the narrative is maturing — the pivotal-trial plan announced on May 8, 2026 remained the central story on September 8, while the September 18 market snapshot showed a three-month price decline of 8.0%. These observations establish an existing clinical story with weak recent price participation; they do not establish widespread ownership. [May 8 development announcement](https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Announces-Positive-Initial-Clinical-Data-with-AlloNK-Across-Multiple-Autoimmune-Diseases-and-FDA-Alignment-to-Initiate-Phase-3-Registrational-Trial-in-Rheumatoid-Arthritis-in-2026/default.aspx)\n\n## Bull Case\n\n- **Funding supports the trial plan.** Artiva reported $349.4 million in cash, cash equivalents and investments at June 30, 2026, and projected funding into 2029. That runway is management’s forecast; expenditure above its assumptions would weaken the funding case. [August 6 financial results](https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n- **Outpatient treatment has been demonstrated.** Artiva’s May 8, 2026 release said all treated patients had received treatment as outpatients, mostly in community rheumatology clinics. This supports the proposed delivery setting; treatment-related hospitalizations in subsequent cohorts would challenge its generalizability. [May 8 clinical update](https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Announces-Positive-Initial-Clinical-Data-with-AlloNK-Across-Multiple-Autoimmune-Diseases-and-FDA-Alignment-to-Initiate-Phase-3-Registrational-Trial-in-Rheumatoid-Arthritis-in-2026/default.aspx)\n\n## Bear Case\n\n- **The response sample remains small.** At the April 3, 2026 cutoff, five of seven patients in the company-sponsored rheumatoid arthritis cohort achieved the American College of Rheumatology 50% response criterion (ACR50) after six months, according to the August 6 release. The sample is too small to support a claim of superiority over rituximab alone. [Results filed with the SEC](https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/artv-ex99_1.htm)\n- The August 6 release also disclosed approximately $300 million raised through an underwritten offering: financing capacity came with additional equity issuance. [August 6 financial results](https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights/default.aspx)\n\n## Setup & Price Structure\n\nThe supplied adjusted market series records a September 18, 2026 close of $8.61, 35.7% below its 52-week high of $13.39. The 14-day relative strength index (RSI) was 13.8. These measured observations describe weak momentum; they do not demonstrate that a base has formed.\n\nThe $8.61 reference close anchors the thesis test because no independently established support shelf is supplied. A weekly close below $8.61 invalidates the proposed stabilization accompanying clinical progress; it does not establish that AlloNK has failed clinically.\n\nThe supplied coverage includes a September 3, 2026 specialist-investor article and a September 8 trial-update headline. That sample is too small to support a crowding claim. Moving-average distance, short interest, fund flows and insider transactions are missing from the available evidence.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-24 — Stifel investor forum.** Artiva is scheduled for a fireside chat at the Stifel Virtual Immunology and Inflammation Forum. The reported announcement specifies a management discussion, without promising a clinical readout. [Company announcement reproduced by BioPharmaWatch](https://www.biopharmawatch.com/news/ARTV/artiva-biotherapeutics-stifel-2026-forum)\n- **2026-12-31 — Milestone-window endpoint, not a scheduled release.** The September 8 update promised second-half data from at least 20 rheumatoid arthritis patients with six-month follow-up and initiation of an approximately 150-patient randomized trial. This later window is the substantive thesis test; the exact disclosure date remains unspecified. [September 8 milestone update](https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Provides-Update-on-Planned-AlloNK-Data-Disclosures-and-Development-Milestones-for-the-Remainder-of-2026/default.aspx)\n\n## What Would Change Our Mind\n\nFailure to retain the September 18 reference close would break the market component: a weekly close below $8.61 ends this thesis. Independently, reaching December 31, 2026 without the promised expanded rheumatoid arthritis disclosure or trial initiation would break the September 8 development timetable.\n\nConfirmation requires the announced clinical milestones before the price invalidation occurs. A conference appearance alone does not satisfy that condition, and the small April 3 cohort cannot settle comparative efficacy.\n\n## Correlation Notes\n\nThis is a single-name clinical setup. The September 18, 2026 evidence contains no matched sector-return series or measured peer correlations, so it supports no claim that a biotechnology group move explains Artiva’s decline. The randomized comparison with rituximab described in the September 8 update is the company-specific test of AlloNK’s incremental contribution. [Trial-design update](https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Provides-Update-on-Planned-AlloNK-Data-Disclosures-and-Development-Milestones-for-the-Remainder-of-2026/default.aspx)",
  "first_seen": "2026-09-14",
  "last_analyzed": "2026-09-19T20:46:10+00:00",
  "last_synthesized": "2026-09-19",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}